18F-FDG PET/CT 预测接受降强度治疗的人乳头瘤病毒阳性局部晚期口咽癌患者的治疗结局:NRG-HN002 研究结果
本研究为 NRG-HN002 Ⅱ期非比较试验的次要终点分析,评估 p16 阳性局部晚期口咽癌患者接受减量放疗±顺铂后 12–14 周 PET/CT 对 2 年无进展生存(PFS)和局部区域控制(LRC)的阴性预测值(NPV)。共 117 例可分析,2 年 PFS 和 LRC 分别为 91.3% 和 93.8%,PET/CT 阴性 115 例(98.3%)。LRC 的 NPV 为 94.5%(90% LCB 90.6%;P=0.07),PFS 的 NPV 为 92.0%(90% LCB 87.7%;P=0.30)。
要点
- 减量放疗后 12–14 周 PET/CT 对 2 年 LRC 的 NPV 估计 >90%,与标准放化疗报道相似。
- 对 2 年 PFS 的 NPV 无充分证据判定 >90%(P=0.30)。
- 可分析组 2 年 PFS 91.3%、LRC 93.8%,PET/CT 阴性者占 98.3%。
核心结论
- 在减量放疗的降强度治疗背景下,治疗后 12–14 周 PET/CT 对 2 年 LRC 的 NPV 估计 >90%,与标准放化疗患者报道相似。
- 然而,无充分证据判定 PET/CT 对 2 年 PFS 的 NPV >90%。
研究设计与样本
- NRG-HN002 为 p16 阳性局部晚期口咽癌(T1-T2、N1-N2b 或 T3、N0-N2b,吸烟 ≤10 包年)的Ⅱ期非比较试验,本研究为其次要终点分析。
- 患者按 1:1 随机接受减量调强放疗联合或不联合顺铂。
- PET/CT 图像集中审阅,采用 5 分有序量表(Hopkins 标准)评估原发灶、右颈和左颈。
主要发现
- 共入组 316 例,随机且符合条件 306 例,其中 131 例(42.8%)同意治疗后 PET/CT,117 例(89.3%)可纳入 PET/CT 分析。
- 从治疗结束至 PET/CT 的中位时间为 94 天(范围 52–139 天)。
- 分析亚组估计 2 年 PFS 为 91.3%(95% CI 84.6–95.8%),2 年 LRC 为 93.8%(95% CI 87.6–97.5%)。
- 治疗后扫描显示 115 例(98.3%)无残留肿瘤(阴性),2 例(1.7%)阳性。
- 2 年 PFS 的 NPV 为 92.0%(90% 置信下限 87.7%;P=0.30),2 年 LRC 的 NPV 为 94.5%(90% 置信下限 90.6%;P=0.07)。
关键数值与推荐
- 阴性预测值假设检验:2 年 PFS 和 LRC 的 NPV ≤90% 对比 >90%(单侧 P 值 0.10)。
- 总体评分:三个评估部位均为阴性者总体评为阴性。
- 肿瘤反应评估采用 5 分有序量表(Hopkins 标准)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 仅 131 例(42.8%)同意治疗后 PET/CT,117 例(89.3%)可分析。
- 无充分证据判定 PET/CT 对 2 年 PFS 的 NPV >90%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this study was to determine the negative predictive value (NPV) of a 12- to 14-wk posttreatment PET/CT for 2-y progression-free survival (PFS) and locoregional control (LRC) in patients with p16-positive locoregionally advanced oropharyngeal cancer (LA-OPC). Study was a secondary endpoint in NRG-HN002, a noncomparative phase II trial in p16-positive LA-OPC, stage T1-T2, N1-N2b or T3, N0-N2b, and ≤10 pack-year smoking. Patients were randomized in a 1:1 ratio to reduced-dose intensity-modulated radiotherapy (IMRT) with or without cisplatin. Methods: PET/CT scans were reviewed centrally. Tumor response evaluations for the primary site, right neck, and left neck were performed using a 5-point ordinal scale (Hopkins criteria). Overall scores were then assigned as negative, positive, or indeterminate. Patients with a negative score for all 3 evaluation sites were given an overall score of negative. The hypotheses were NPV for PFS and LRC at 2-y posttreatment ≤ 90% versus >90% (1-sided P value, 0.10). Results: A total of 316 patients were enrolled, of whom 306 were randomized and eligible. Of these, 131 (42.8%) patients consented to a posttherapy PET/CT, and 117 (89.3%) patients were eligible for PET/CT analysis. The median time from the end of treatment to PET/CT scan was 94 d (range, 52-139 d). Estimated 2-y PFS and LRC rates in the analysis subgroup were 91.3% (95% CI, 84.6, 95.8%) and 93.8% (95% CI, 87.6, 97.5%), respectively. Posttreatment scans were negative for residual tumor for 115 patients (98.3%) and positive for 2 patients (1.7%). NPV for 2-y PFS was 92.0% (90% lower confidence bound [LCB] 87.7%; P = 0.30) and for LRC was 94.5% (90% LCB 90.6%; P = 0.07). Conclusion: In the context of deintensification with reduced-dose radiation, the NPV of a 12- to 14-wk posttherapy PET/CT for 2-y LRC is estimated to be >90%, similar to that reported for patients receiving standard chemoradiation. However, there is insufficient evidence to conclude that the NPV is >90% for PFS.
引用
- Subramaniam RM, DeMora L, Yao M, et al. 18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus-Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002. J Nucl Med. 2022. PMID: 36215572. doi:10.2967/jnumed.122.264424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。